Cell and gene therapies are driving M&A deal activity

Adam Golden and Anishiya Abrol authored the article "Cell And Gene Therapies Are Driving M&A Deal Activity" which was published in Law360.

Advances in the development of cell and gene therapies present new approaches to the treatment and prevention of certain diseases which have proven resistant to traditional drugs or therapies.

Golden and Abrol discuss collaborations between biopharma companies and financings for the development of cell and genetic therapies, as well as licensing for manufacturing technology. The considerations for deals and licensing in the field are outlined.

Read More: Cell and gene therapies are driving M&A deal activity

This article originally appeared in Law360 here (login required).


Back To Listing
Loading data